Quantcast

Latest hyperglycemia Stories

2009-10-13 17:56:00

CARLSBAD, Calif., Oct. 13 /PRNewswire/ -- Luminous Medical, Inc. announced today that it has reached agreement with a major supplier of electrochemical sensors for exclusive rights to incorporate its glucose sensor into Luminous' automated blood glucose monitor. Luminous is developing its monitor to enable clinicians to control hyperglycemia in critical care patients around the world. Previously, Luminous was planning to use a sensing technology based on near-infrared spectrometry....

2009-09-30 01:30:00

PARIS, September 30 /PRNewswire-FirstCall/ -- - 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R) Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the...

2009-09-09 09:39:40

Studies link improvements in diabetes control to frequency of use and demonstrate continued improvements 12 months after use, with 'remarkably low' occurrence of severe hypoglycemia The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors "“ six days per week or more "“ rather than the age of patients, and that...

2009-08-26 07:45:12

Mild glucose intolerance in pregnancy may be an early identifier of women who are at increased risk of heart disease in the future, according to a new Canadian study. As cardiovascular disease is the leading cause of death in Canadian women, it is important to identify early predictors of future vascular risk. While women with gestational diabetes have a higher risk of cardiovascular disease than those without, researchers did not know whether mild glucose intolerance in pregnancy is...

2009-07-30 06:30:30

Older diabetic patients who take antipsychotic medications appear to have an increased risk of hospitalization for hyperglycemia (elevated blood glucose level), especially soon after beginning treatment, according to a new report. The antipsychotic drugs prescribed for older adults with dementia may be associated with adverse effects, including Parkinson's disease symptoms, stroke and diabetes. "The risk of diabetes may be partly related to chronic effects of the weight gain associated with...

2009-06-24 12:25:00

Preliminary Data Demonstrates Reduction of HbA1c Levels With Doses an Order of Magnitude Lower than the Dose Used in the Current Phase 3 Trial. BETHESDA, Md., June 24 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq CM: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced positive preliminary results from a Phase 2 clinical trial of its...

2009-06-23 10:33:00

Kid Delegates Meet Elected Officials, Testify at Senate Hearing, and Urge Legislators To Request Fund Research WASHINGTON, June 23 /PRNewswire-USNewswire/ -- More than 150 children and teenagers throughout the U.S. with type 1 diabetes are in Washington, D.C. this week to advocate for funding for type 1 diabetes research. They'll be joined by JDRF International Chairman Mary Tyler Moore, Nick Jonas of the Grammy nominated multi platinum group The Jonas Brothers, boxing legend Sugar Ray...

2009-06-09 07:00:00

- SYNCHRONY Study Published in The Lancet Supports Cardio-Protective Potential of Aleglitazar - NUTLEY, N.J., June 9 /PRNewswire/ -- Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. This decision is supported by data from the Phase II SYNCHRONY study published today in The Lancet(1) and announced at...

2009-06-06 10:00:00

- A1C and FBG Results for Patients 65 and Under Treated with Lantus and NPH were Similar - NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. presented results of a new study, "Safety and Efficacy of Insulin Glargine Compared With NPH Insulin in Older Adults With Type 2 Diabetes: Results from a Pooled Analysis," that examined the safety and efficacy of Lantus(R) (insulin glargine [rDNA origin] injection) compared to insulin NPH in older adults with type 2 diabetes. The study,...

2009-06-06 10:00:00

RIDGEFIELD, Conn., June 6 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced its pipeline of oral antidiabetic compounds, establishing itself in the type 2 diabetes therapeutic area. The Company is investigating compounds in Phase II and Phase III clinical development worldwide. New Phase II data results for linagliptin (BI 1356), a dipeptidyl peptidase 4 (DPP-4) inhibitor and the Company's lead diabetes compound, were presented today at the 69th Annual American...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related